share_log

Immuneering | 8-K: Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 -

SEC ·  Aug 7 04:16
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more